Anti-GLG1 antibody

  • Description

  • Application Data

Description

An antibody raised against Golgi apparatus protein 1 (GLG1); also known as E-selectin ligand-1 (ESL-1), it is a golgi apparatus-localized protein which acts in osteoblasts to regulate bone homeostasis.

See full description

Application Data

Catalogue number crb2005703
Antibody Anti-GLG1 antibody
Antigen Peptide KLH conjugated synthetic peptide crb1200912
Protein ID UniProtKB - Q92896
Aliases Golgi apparatus protein 1, Cysteine-rich fibroblast growth factor receptor, CFR-1, E-selectin ligand 1, ESL-1, Golgi sialoglycoprotein MG-160, GLG1, CFR1, ESL1, MG160
Cross-Reactivity Human, Mouse, Rat
Host Species Rabbit
Antibody Type Polyclonal
Concentration 0.5 mg/ml Glycine (R1G), 1 mg/ml Glycine (R2G)
Target GLG1
Storage This material is supplied in PBS containing 0.01% sodium azide and 1% trehalose. The product should be stored at +4°C for short term storage and -20°C for long term storage. Avoid repeated freeze/thaw cycles.
Data Sheet Data Sheet Material Safety Data Sheet (MSDS)

GLG1 as an important regulator of bone remodelling which localises to the Golgi apparatus. It functions to maintain a balanced bone homeostasis where it can play either a catabolic or anabolic role. GLG1 regulates TGF-β maturation during cartilage homeostasis. GLG1 is also a novel adiponectin (APN)-binding protein. APN is an adipocyte-derived bioactive molecule with anti-diabetic and anti-atherogenic properties. GLG1 is also a novel polysialic acid (polySia) acceptor. PolySia is a protein-modifying glycan implicated in modulating microglia activity.

GLG1 acts in the initial process to tether leukocytes to vascular endothelium however, this role has been implicated in the method tumour cells are able to progress and migrate. GLG1 has also been linked to the Lou Gehrig’s disease also known as Amyotrophic Lateral Sclerosis 1 (ALS1).

Anti-GLG1 antibody

Cat No.Pack SizePriceQty.
20ug£50.00
20ug£50.00
Bulk Quote